Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00744055 · ClinicalTrials.gov registry record · Phase 3
Prazosin for Treatment of Patients With Alcohol Dependence (AD) and Post Traumatic Stress Disorder (PTSD).
A Phase 3 study of Stress Disorders, Post-Traumatic and Alcohol Dependence, sponsored by Yale University.
- Completed
- Registry status
- Phase 3
- Development phase
- 96
- Enrollment target
- 1
- Study location
NCT00744055 is a Phase 3 study of Stress Disorders, Post-Traumatic and Alcohol Dependence that has completed, run by Yale University. The registered enrollment target is 96 participants, below the 154-participant average among 64 other Stress Disorders, Post-Traumatic trials with a reported enrollment target (38% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00744055, a Phase 3 study of Stress Disorders, Post-Traumatic and Alcohol Dependence, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 96 participants
- Enrollment target
- 1
- Study location
Study Summary
Prazosin is an alpha-1 adrenergic receptor antagonist that has been used successfully in the treatment of trauma nightmares and sleep disturbance in combat veterans with PTSD, and alcohol dependence. The objective of this study is to evaluate the efficacy of prazosin (16mg) versus placebo in reducing alcohol consumption and decreasing symptoms of PTSD in patients with comorbid AD and PTSD.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Prazosin
Study Locations (1)
Connecticut
- VA Connecticut Healthcare System - West Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2009-01 |
| Est. Completion | 2014-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00744055
The ClinicalTrials.gov registry entry for NCT00744055 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 154-participant average among 64 other Stress Disorders, Post-Traumatic trials with a reported enrollment target (38% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Stress Disorders, Post-Traumatic appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00744055 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT00744055 about?
NCT00744055 is a clinical study titled "Prazosin for Treatment of Patients With Alcohol Dependence (AD) and Post Traumatic Stress Disorder (PTSD).". Prazosin is an alpha-1 adrenergic receptor antagonist that has been used successfully in the treatment of trauma nightmares and sleep disturbance in combat veterans with PTSD, and alcohol dependence. The objective of this study is to evaluate the efficacy of prazosin (16mg) versus placebo in reduci...
What is the current status of trial NCT00744055?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 96 participants. The study started on 2009-01. Estimated completion is 2014-10.
What conditions does trial NCT00744055 study?
This clinical trial studies the following conditions: Stress Disorders, Post-Traumatic, Alcohol Dependence.
What interventions are being tested in trial NCT00744055?
The interventions under investigation include: Placebo (DRUG), Prazosin (DRUG).
Who is sponsoring clinical trial NCT00744055?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00744055 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stress Disorders, Post-Traumatic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Fluoxetine vs EMDR to Treat Post-Traumatic Stress Disorder (PTSD)
COMPLETED · Phase 3
-
Cognitive Behavioral Therapy (CBT) for Posttraumatic Stress Disorder (PTSD) in Community Addiction Treatment
COMPLETED · Phase 3
-
Manage Emotions to Reduce Aggression (MERA)
RECRUITING · NA
-
SMART Therapist Training: A Hybrid Factorial-SMART Design
RECRUITING · NA
-
Overcontrol and Suicide in PTSD
RECRUITING
-
Postpartum Care in the NICU (PeliCaN) Transitions
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.